Gilead, J&J Sue Lupin, MSN Labs to Block Copies of Symtuza Drug

Gilead and J&J’s Janssen said a generic version of Symtuza proposed by Lupin and its business partner MSN Laboratories infringes four Gilead patents for the four-drug combination, used to treat HIV-1.

• Gilead and J&J seek court orders blocking copies until patents have expired and blocking FDA approval of copies until July 2038: complaint filed Tuesday in federal court in Wilmington, Delaware
  • Patents expire in April 2030, October 2031, October 2032 and July 2038: supplemental filing
• Gilead on Monday sued Lupin in Delaware over two other Symtuza patents expiring in August 2032
• Symtuza is four-drug combination of darunavir, cobicistat, emtricitabine ...